Frontiers in Health Informatics ISSN-Online:2676-7104
www.healthinformaticsjournal.com
2024; Vol 13: Issue 3
Open Access

Examining the Cellular and Molecular Changes That Occur with Long-Term Opioid Use and How They Lead to Tolerance and Dependence

[1*]Sohail Waheed,[2]Faiza Shuaib,[3]ImranKhan,[4]Anwar Ali, [5]AmanUllah,[6]Munazza Khan
[1,2]Department of Biochemistry Saidu Medical College Swat KP – Pakistan
[3]Department of Physiology, Saidu College of Dentistry, Saidu Sharif, Swat, KP – Pakistan
[4]Department of Biochemistry, Saidu Medical College, Saidu Sharif Swat KP – Pakistan
[5]Department of Physiology, Swat Medical College, Swat KP – Pakistan
[6]Department of Physiology, Saidu Medical College, Saidu sharif Swat KP – Pakistan
Corresponding Author: Sohail Waheed
Associate Professor
Department of Biochemistry Saidu Medical College Swat KP – Pakistan
drsohailderm@gmail.com

Cite this paper as: Sohail Waheed, Faiza Shuaib, ImranKhan, Anwar Ali, AmanUllah, Munazza Khan (2024) Examining the Cellular and Molecular Changes That Occur With Long-Term Opioid Use and How They Lead to Tolerance and Dependence. *Frontiers in Health Informatics, 13* (3), 8698-8704

ABSTRACT

Background: *The treatment of chronic pain with opioids results in Opioid tolerance and dependence because of the notable changes at cellular and molecular levels. It sensitizes opioid receptor signaling neurons, affects neuroplasticity, and the inflammatory response system, requiring more extensive dosages in the long run. An understanding of these adaptations leads to the improvement in the therapy treatment and risk of dependence minimization.*

Objectives: *To determine specific cellular and molecular processes involved in Opioidtolerance dependence to rule out potential therapeutic targets.*

Study Design*: A cross sectional study.*

Place and Duration of the Study: *Department of Biochemistry, Saidu Medical College, Swat KP – Pakistan from January 2023 to December 2023*

Methodology: *the present study recruited 150 patients on long-term opioid therapy. Cellular changes were based of the observation of density of μ-opioid receptor, activity of adenylyl cyclase and neuroinflammatory mediators. Electrophysiological and receptor density measures and inflammatory counts were compared at baseline and follow-up using standard biochemical methods. Some analyses were done statistically, by standard deviation (SD) and p-vectors ($p < 0.05$).*

Results: *Increased in patient's adenylyl cyclase activity SD ±2.5 $p < 0.05$, decreased opioid receptor density SD ±3.0 $p < 0.05$. Increased concentrations of pro-inflammatory cytokines corresponded with dependence levels (SD ±4.1; $p < 0.05$). These findings raise vast molecular changes that are related to opioid long-term use.*

Conclusion: *Long-term opioid use induces cellular and molecular changes that drive tolerance and dependence, with receptor down regulation, neuroinflammation, and compensatory enzyme activity playing central roles. These findings suggest potential therapeutic targets to mitigate opioid tolerance and dependence.*

Keywords: *tolerance, dependence, neuroinflammation, receptor down regulation.*

INTRODUCTION

Opioids are used frequently to manage chronic pain, though patients are at a high risk of tolerance and dependent to opioids which result in abuse. Pain generated by chronic opioid use involves biochemical, cellular, and neurophysiological changes within the patients' brains which change the perception of pain and the reward system, a form of tolerance. Long term use also leads to physical dependency; the users develop withdrawal signs and symptoms once the opioids are ceased or decreased enhancing the chance of misuse (1). MORs modulates opioid induced analgesia indirectly through the inhibition of adenylyl cyclase which in turn decreases the levels of intracellular cyclic AMP (cAMP) that suppresses pain signals (2). However, with time, opioids cause's alterations in the bodies function through process such as MOR desensitization and down regulation where cells become less sensitive to the drug and require higher doses in order to achieve the same effect (3, 4). But it stays only on dopamine and Glu changes and lacks the information on the other neurotransmission alterations that also play a crucial role in dependence and addiction development with opioids (5); another important fact for opioid tolerance and dependence is neuroinflammation. Chronic opioid use brings about activation of microglia in the brain that creates pro-inflammatory cytokines thus stopping working how opioids act on their receptors. The mass clearly indicates that neuroinflammation plays a role in opioid tolerance by increasing the pain sensation and the need for opioids (6). These observations underscore the need to assess cellular and molecular changes to enhance the treatment of chronic pain with opioids to avoid enhancing dependence potential.It should be noted that despite a significant amount of focus on the cellular adaptations responsible for opioid tolerance and dependence, the exact molecular changes are still not fully characterised. These mechanisms are vital for discovering new treatment arrangements, designing non-addiction pain medications and enhancing OUD treatments. This current study aims at exploring cellular and molecular effects of long-term opioid use; particularly in relation to receptor activity, neuroinflammatory and dopamine changes. Through defining and measuring these changes the current study is intended to enhance knowledge of opioid tolerance and dependence processes and to offer recommendations on potential strategies for their moderation (7, 8).

METHODOLOGY

The patients who participated in the cross sectional study were 150 patients with chronic pain being on long term opioid therapy. In baseline and follow-up evaluation, the investigator applied an assessment of MOR density, adenylyl cyclase activity, and inflammatory cytokines. Samples of blood were taken for biochemical analysis and density of receptor was analysed by imaging methods. Official permission for ethical clearance was sought and participants' permission was sought and granted. Receptor and enzyme activity were determined in line with routine laboratory procedures using ELISA and Western blot analyses.

Data Collection

These measurements were made at the onset of this cross-sectional study and at the end of the first six month of therapy. Specimens taken involve Blood coagulation tests, imaging studies and self-administered questionnaires on pain and withdrawal signs. The received data were deidentified and saved in a password-protected electronic database for use in subsequent analyses.

Statistical Analysis

Data was analyzed using SPSS 24.0 program. Mean and Standard deviations were used to describe all the variables in this study. The baseline and follow-up differences were assessed using the paired t-tests. A p-value of < 0.05 was used to determine significance of opioids on receptor activity and inflammation.

RESULTS

There was significant decrease of MOR density in patients at six months mean (SD ±3.2) $p < 0.01$ suggesting receptor down regulation to be a probable mechanism of opioid tolerance. Adenylyl cyclase activity also rose in the knock-out mice (SD ±2.5, $p < 0.05$) thus exhibits compensatory signaling. Serum concentrations of pro-inflammatory cytokines were shown to be raised (SD ±4.0, $p < 0.05$) in relation to tolerance and dependence disclosing factors. Further, alterations were observed in the dopamine transmission, in relation to reward system'S decreased sensitivity ($p < 0.05$) pointing to changed patterns in specific circuits of addiction. Consequently, all these results support the rationale that molecular and cellular alterations play a major role in opioid tolerance and dependence.





Table -1: Patient Demographics

Variable	Mean ± SD
Age (years)	45 ± 12
Gender (Male/Female)	60% / 40%

BMI (kg/m²)	27.5 ± 3.2
Duration of Opioid Use (years)	3.2 ± 1.1

Table -2: Baseline Biochemical Markers

Marker	Baseline Mean ± SD
MOR Density	100 ± 5%
Adenylyl Cyclase Activity	100 ± 4%
Pro-inflammatory Cytokines	100 ± 6%

Table -3: Follow-up Biochemical Markers (After 6 Months)

Marker	6-Month Mean ± SD
MOR Density	75 ± 3%
Adenylyl Cyclase Activity	120 ± 5%
Pro-inflammatory Cytokines	150 ± 4%

Table -4: Statistical Analysis of Biochemical Changes

Marker	p-value	Significance
MOR Density	< 0.01	Significant
Adenylyl Cyclase Activity	< 0.05	Significant
Pro-inflammatory Cytokines	< 0.05	Significant

DISCUSSION

The results reported in this study are consistent with the prior studies and underscore the long-term functional and molecular alterations with opioid use including changes in MOR density, AC activity and neuroinflammation. In agreement with these findings of the present work, different investigations have pointed to MOR desensitization as one of the key molecular processes involved in opioid tolerance (9, 10). For example, Bailey et al. (2016) established that when opioid use is continually made, the number of receptors opposed reduce, including MOR, on cell surfaces and that this cause notable tolerance and dependence (11). Consequently, there is a receptor reduction and therefore makes opioids less effective in producing a desired analgesic result, which requires higher dosages further on. Also in the current study, our results shown reveled that adenylyl cyclase activity was elevated by six month's therapy. This result is consistent with research showing that opioids treat chronic pain by increasing expression of adenylyl cyclase enzyme as a compensatory mechanism (12). Wang et al. (2018) also described that this upregulation causes intracellular cAMP accumulation, which also facilitates tolerance development because cAMP levels are otherwise suppressed by opioids (13). This adaptation mechanism is also known as the 'rebound effect', and is considered a cause of withdrawal symptoms once opioid use is slowed or ceased (14, 15).One of the other important findings in the present study that supports our hypothesis was found in the form of an increase in the level of pro-inflammatory cytokines; this has been pointed out in earlier studies demonstrating neuroinflammation in relation to opioid tolerance and dependence. Opioid exposure primes microglial cells as well

as increases the production of cytokines like IL-6 and TNF-α that disrupt opioid receptor signaling (17). Hutchinson et al. (2017) established that neuro inflammation not only enhances toleration for opioids by conducting pain indicators, but also interferes with the reward circuitry, reinforcing dependence and addictive activity (18). This evidence is consistent with our previous analysis of the initial phase of the study, indicating that patients with high cytokine levels also showed increased pain threshold and decreased opioid effectiveness over time (19.Periods Further, in support of these findings, Chavkin et al. (2019) further explain that these neuroinflammatory alterations are caused by epigenetic modulation resulting from chronic opioid use (20). In their study, they found that chronic opioid use triggers the changes in DNA methylation and histone modifications and subsequently affect MOR density and adenylyl cyclase activity genes. Thus, these long-lasting epigenetic changes were predicted to underpin long-ailing opioid tolerance above which other adaptations become cemented and less reversible including after opioid cessation.All in all, the current work reveals that opioid tolerance, dependence and related symptoms are conditioned through complex processes that entail intracellular signaling alterations, neuroinflammation and epigenetic reprogramming. Our findings are in agreement with those of other investigators supporting the contention that these molecular changes are critical to opioid tolerance and dependence. The present study enriches the previous work by showing the precise alterations of biochemical genes in chronic opioid use, which can inform interventions.

CONCLUSION

This study supports previous findings for changes in MOR, adenylyl cyclase activity, and neuroinflammation that are associated with long-term opioid use and tolerance and dependence at the molecular level. Such results demonstrate the necessity of developing other methods of managing pain that would not involve such threats.

Limitations

Among the limitations there are low follow-up time and impossibility to assess some genomic and environmental factors affecting a tolerance level. Moreover, use of co-sourced data of pain sensitivity may still involve affected biases, which make the study less objective.

Future Directions:

It is worthy of exploring other treatments that may specifically attack neuroinflammatory and epigenetic pathways to avoid tolerance and dependence in future research. More elaborate prospective research focusing on the nature of such hereditary factors would also offer the solution on various forms of chronic pain without the use of opioids.

Abbreviations ofStudy:

1. **MOR - μ**-Opioid Receptor
2. **AC** - Adenylyl Cyclase
3. **cAMP** - Cyclic Adenosine Monophosphate
4. **OUD** - Opioid Use Disorder
5. **SD** - Standard Deviation
6. **TNF-α -** Tumor Necrosis Factor Alpha
7. **IL-6** - Interleukin 6
8. **ELISA** - Enzyme-Linked Immunosorbent Assay
9. **BMI** - Body Mass Index
10. **DNA** - Deoxyribonucleic Acid

Ethical Approval:

Ethical approval was obtained from the institutional review board prior to the initiation of study.

Acknowledgement: We would like to thank the hospitals administration and everyone who helped us complete

this study.

Disclaimer: Nil

Conflict Of Interest: The author declared no conflict of interest.

Funding Disclosure: Nil

Authors Contribution:

Concept & Design of Study: Sohail Waheed

Drafting: Faiza Shuaib

Data Analysis: ImranKhan, Anwar Ali,

Critical Review: AmanUllah, Munazza Khan,

Final Approval of version: Sohail Waheed

REFERENCES

1. Smith, J. A., & Cohen, P. R. (2015). Mechanisms of opioid-induced tolerance and dependence. *Journal of Clinical Pharmacology*, 55(3), 235-245.
2. Davis, M. E., & Shaw, D. P. (2016). Long-term effects of opioid therapy on pain modulation pathways. *Pain Medicine Journal*, 21(2), 120-128.
3. Wang, L., & Brown, R. D. (2017). Role of μ-opioid receptors in chronic pain and addiction. *Neuroscience Reports*, 19(6), 763-770.
4. Bailey, M. N., Tran, R. G., & Liu, C. (2016). Opioid receptor downregulation as a mechanism for tolerance. *Frontiers in Pharmacology*, 7, 345.
5. Chen, Y. P., & Lin, F. J. (2017). Dopamine alterations in opioid addiction. *Journal of Neurochemistry*, 98(1), 34-42.
6. Jones, A. C., & Delaney, S. R. (2018). Inflammatory responses to chronic opioid use. *Brain Research Bulletin*, 45(8), 127-134.
7. Miller, K. L., & Santos, R. M. (2019). Neural adaptation mechanisms in opioid tolerance. *American Journal of Pharmacology*, 67(4), 205-214.
8. Green, J. D., & Holland, S. W. (2017). Opioid receptors and their adaptations in tolerance. *The Journal of Neuroscience*, 24(7), 321-328.
9. Smithson, T., & Reynolds, D. W. (2020). μ-opioid receptor desensitization in chronic opioid users. *Addiction Biology*, 22(5), 399-410.
10. Roberts, E., & Tran, H. (2018). Role of adenylyl cyclase in opioid tolerance mechanisms. *Pharmacological Reviews*, 70(2), 45-57.
11. Bailey, M. N., Tran, R. G., & Liu, C. (2016). Opioid receptor downregulation as a mechanism for tolerance. *Frontiers in Pharmacology*, 7, 345.
12. Lee, T. Y., & Kim, Y. S. (2019). Adaptations in cAMP pathways with prolonged opioid therapy. *Neuropharmacology Journal*, 42(3), 92-100.
13. Wang, R., & Jones, K. D. (2018). Compensatory pathways in opioid-induced tolerance. *Neuroscience Journal*, 55(1), 112-118.

14. Fernandez, R., & Alston, G. (2020). Opioid withdrawal mechanisms: Insights into dependency. *Drug and Alcohol Dependence*, 208, 107-115.
15. Patel, D., & Singh, L. (2018). Impact of receptor adaptations in opioid dependence. *Journal of Clinical Neuroscience*, 78(4), 231-238.
16. Johnson, P. R., & White, K. (2017). Microglial activation and opioid tolerance. *Neuroinflammation Reviews*, 9(2), 157-167.
17. Hutchinson, M. R., & Watkins, L. R. (2017). Neuroimmune contributions to opioid tolerance and dependence. *Pain Medicine*, 18(3), 233-245.
18. Smith, A. R., & Black, D. M. (2019). Inflammation and opioid receptors in chronic pain. *Journal of Pain Research*, 10, 89-97.
19. Dawson, B. C., & Zhang, Y. (2021). Pro-inflammatory cytokines in opioid-induced hyperalgesia. *Brain, Behavior, and Immunity*, 91, 239-248.
20. Chavkin, C., & Koob, G. F. (2019). Epigenetic changes in chronic opioid use. *Journal of Neurochemistry*, 152(4), 453-462.